[The effects of angiotensin II receptor blockers in hypertensive patients complicating hyperuricaemia].

What Was Tested

This randomized controlled trial looks at Losartan.

To study the effects of angiotensin II receptor blockers (ARB), losartan and irbesartan, on blood pressure and serum uric acid (SUA) level in mild to moderate essential hypertensive patients complicating hyperuricaemia.

Who Took Part

The abstract describes 351 patients taking part.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

A total of 351 eligible patients were recruited in this multi-center, randomized, double-blind parallel clinical trial.

How the Study Was Run

The design is described as randomized, double-blind, single-blind, placebo-controlled and parallel-group.

The patients were allocated by chance, so the Losartan group and the comparison group should start out alike.

Neither the patients nor the staff measuring them knew who was on Losartan, so expectations could not easily colour the readings.

Only one side, usually the patients, was kept unaware of whether Losartan was given.

Some patients received a placebo instead of Losartan, giving a reference point.

The SUA concentration and blood pressure were measured at baseline, 4 and 8 weeks post therapy.

What Was Measured

PubMed files the paper under topics including Angiotensin II Type 1 Receptor Blockers, Biphenyl Compounds, Hypertension, Irbesartan, Losartan, Tetrazoles and Uric Acid.

What This Means in Plain Language

The paper is a randomized, double-blind and single-blind study of Losartan in 351 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2006 (Zhonghua xin xue guan bing za zhi), a journal based in China.

More context: all human trials.